Synaptogenix, Inc. (SNPX)
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK, NY 10036
Founded
2012
Number of Employees
8
Website
http://www.synaptogen.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)